Compare Li Auto Inc (LI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Li Auto Inc trades at $11.54 (market cap $10.71B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Li Auto Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LI | XBI | |
|---|---|---|
Market Cap | $10.71B | $10.11B |
Volume | 1,781,143 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $23.13 | $169.55 |
52-Week Low | $10.69 | $104.99 |
Typical Hold Time | 101 Days | 38 Days |
Enterprise Value | $139.58M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows, reflecting bearish technical signals and recent earnings misses. The company reported declining revenue ($112.31B in 2025) and negative net income margins (-4.4%), though valuation metrics like P/S (0.73) appear attractive. Recent news highlights delivery moderation and new model launches (Li i9, Li MEGA) amid intense EV competition.
The stock faces near-term headwinds from cash burn and competitive pressures, but analyst consensus remains cautiously optimistic with a $15.18 price target. Key risks include execution challenges in global expansion and margin recovery, while potential upside hinges on successful product cycles and cost management improvements.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
